The Form 4 filing, an SEC report of insider stock activity, was filed on Nov. 18, 2026. It came one day after the trades by Martine A. Rothblatt, chairperson and CEO of United Therapeutics (UTHR).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-17 |
| Date of Latest Transaction | 2026-11-17 |
| Buy/Sell | sell |
| Transaction Count | 11 |
| Shares Transacted | 9,500 |
| Price | $580.43 |
| Total Transaction Value | $5,514,046.05 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported with transaction code S. The filing covers 11 sale transactions, all dated Nov. 17, 2026.
What was the average price of the transaction?
The average sale price was $580.43 per share, rounded to cents. That average covers the 9,500 shares sold across the 11 reported transactions.
How did this transaction affect the insider's holdings?
The sales reduced the reported holdings by 9,500 shares, leaving 324,443 shares. The shares sold made up 2.84% of the shares owned before the sales.
What's the total transaction value?
The 11 transactions had a total value of $5,514,046.05. That figure is rounded to cents from the recorded value of $5,514,046.0498.
Are there any special circumstances around this transaction?
The available details include a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. The reference may come from a checkbox covering the whole filing, so its scope across the 11 sales is unclear. No footnote text is available to confirm which sales it covers. The plan's start date, trading schedule, and other terms are unknown.
For research purposes only; not investment advice.